KRAS and non-small cell lung carcinoma: Patients whose tumors harbor KRAS/TP53 co-mutations have been associated with an improved response to ICIs in NSCLC, whereas those with LKB1/STK11 and KEAP1 mutations have been associated with poorer responses [21,31].